Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.

Alban, Juan; DuVall, Adam; Gurbuxani, Sandeep; Stock, Wendy; Patel, Anand Ashwin

Alban, Juan; DuVall, Adam; Gurbuxani, Sandeep; Stock, Wendy; Patel, Anand Ashwin.

Afiliação

Alban J; Department of Medicine, University of Chicago, Chicago, IL.
DuVall A; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.
Gurbuxani S; Section of Hematopathology, Department of Pathology, University of Chicago, Chicago, IL.
Stock W; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.
Patel AA; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.

JCO Precis Oncol ; 6: e2200353, 2022 10.

Article em En | MEDLINE | ID: mdl-36240471

Assuntos

Linfoma de Células B; Leucemia-Linfoma Linfoblástico de Células Precursoras; Humanos; Inotuzumab Ozogamicina; Cromossomo Filadélfia; Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico; Retratamento

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Leucemia-Linfoma Linfoblástico de Células Precursoras Limite: Humans Idioma: En Revista: JCO Precis Oncol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google